| ACTI Stock | | | SEK 0.27 0.02 8.00% |
Executive
Ms. Helen Tuvesson was appointed President and Chief Executive Officer at Active Biotech AB effective as of July 1, 2017. She has previously served as Chief Scientific Officer at Active Biotech AB since April 1, 2011. She was previously Head of Preclinical Development at the Company until April 1, 2011 since 2017.
| Age | 61 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 46 46 19 20 00 |
| Web | https://www.activebiotech.com |
Tuvesson was employed at the Company since 1998. She has worked in the pharmaceutical industry for almost 20 years and has held various positions at Pharmacia. She is Doctor of Cellular and Molecular Biology from Lunds universitet.
Active Biotech Management Efficiency
The company has return on total asset
(ROA) of
(0.6714) % which means that it has lost $0.6714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.4389) %, meaning that it generated substantial loss on money invested by shareholders. Active Biotech's management efficiency ratios could be used to measure how well Active Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Active Biotech AB has accumulated 200
K in total debt with debt to equity ratio
(D/E) of 268.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Active Biotech AB has a current ratio of 1.34, which is within standard range for the sector. Debt can assist Active Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Active Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Active Biotech AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Active to invest in growth at high rates of return. When we think about Active Biotech's use of debt, we should always consider it together with cash and equity.
Similar Executives
Active Biotech AB , a biotechnology company, develops drugs for the treatment of neurodegenerative diseases, autoimmunityinflammatory, and cancer. Active Biotech AB was incorporated in 1982 and is based in Lund, Sweden. Active Biotech operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people. Active Biotech AB (ACTI) is traded on Stockholm Exchange in Sweden and employs 9 people.
Management Performance
Active Biotech AB Management Team
Elected by the shareholders, the Active Biotech's board of directors comprises two types of representatives: Active Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Active. The board's role is to monitor Active Biotech's management team and ensure that shareholders' interests are well served. Active Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Active Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Active Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Active Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Active Stock Analysis
When running Active Biotech's price analysis, check to
measure Active Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Active Biotech is operating at the current time. Most of Active Biotech's value examination focuses on studying past and present price action to
predict the probability of Active Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Active Biotech's price. Additionally, you may evaluate how the addition of Active Biotech to your portfolios can decrease your overall portfolio volatility.